These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

842 related articles for article (PubMed ID: 15308713)

  • 41. Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons.
    Corbet S; Vinner L; Hougaard DM; Bryder K; Nielsen HV; Nielsen C; Fomsgaard A
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1997-2008. PubMed ID: 11153083
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of immune responses induced by combined clade-A HIV-1 recombinant adenovectors in mice.
    Bayanolhagh S; Alinezhad M; Kamali K; Foroughi M; Khorram Khorshid HR; Mohraz M; Mahboudi F; Pourfathollah AA
    Iran J Immunol; 2010 Sep; 7(3):162-76. PubMed ID: 20876987
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost.
    Billaut-Mulot O; Idziorek T; Loyens M; Capron A; Bahr GM
    Vaccine; 2001 Apr; 19(20-22):2803-11. PubMed ID: 11282190
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques.
    Fuller DH; Shipley T; Allen TM; Fuller JT; Wu MS; Horton H; Wilson N; Widera G; Watkins DI
    Virology; 2007 Aug; 364(2):245-55. PubMed ID: 17428516
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo.
    Muthumani K; Zhang D; Dayes NS; Hwang DS; Calarota SA; Choo AY; Boyer JD; Weiner DB
    Virology; 2003 Sep; 314(1):134-46. PubMed ID: 14517067
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
    Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
    Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice.
    Bruce CB; Akrigg A; Sharpe SA; Hanke T; Wilkinson GWG; Cranage MP
    J Gen Virol; 1999 Oct; 80 ( Pt 10)():2621-2628. PubMed ID: 10573155
    [TBL] [Abstract][Full Text] [Related]  

  • 48. DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates.
    Wang B; Boyer J; Srikantan V; Coney L; Carrano R; Phan C; Merva M; Dang K; Agadjanan M; Gilbert L
    DNA Cell Biol; 1993 Nov; 12(9):799-805. PubMed ID: 8216851
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.
    Agwale SM; Shata MT; Reitz MS; Kalyanaraman VS; Gallo RC; Popovic M; Hone DM
    Proc Natl Acad Sci U S A; 2002 Jul; 99(15):10037-41. PubMed ID: 12096189
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dendritic cell-based vaccine strategy against human immunodeficiency virus clade C: skewing the immune response toward a helper T cell type 2 profile.
    Gruber A; Chalmers AS; Rasmussen RA; Ong H; Popov S; Andersen J; Hu SL; Ruprecht RM
    Viral Immunol; 2007; 20(1):160-9. PubMed ID: 17425430
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions.
    Weaver EA; Camacho ZT; Gao F
    AIDS Res Hum Retroviruses; 2010 May; 26(5):577-84. PubMed ID: 20438382
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of a peptide capable of inducing an HIV-1 Tat-specific CTL response.
    Morris CB; Thanawastien A; Sullivan DE; Clements JD
    Vaccine; 2001 Oct; 20(1-2):12-5. PubMed ID: 11567739
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multiple Approaches for Increasing the Immunogenicity of an Epitope-Based Anti-HIV Vaccine.
    Rosa DS; Ribeiro SP; Fonseca SG; Almeida RR; Santana VC; Apostólico Jde S; Kalil J; Cunha-Neto E
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1077-88. PubMed ID: 26149745
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus.
    Xin KQ; Urabe M; Yang J; Nomiyama K; Mizukami H; Hamajima K; Nomiyama H; Saito T; Imai M; Monahan J; Okuda K; Ozawa K; Okuda K
    Hum Gene Ther; 2001 Jun; 12(9):1047-61. PubMed ID: 11399227
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.
    zur Megede J; Chen MC; Doe B; Schaefer M; Greer CE; Selby M; Otten GR; Barnett SW
    J Virol; 2000 Mar; 74(6):2628-35. PubMed ID: 10684277
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNA-vaccinated mice.
    Gao F; Li Y; Decker JM; Peyerl FW; Bibollet-Ruche F; Rodenburg CM; Chen Y; Shaw DR; Allen S; Musonda R; Shaw GM; Zajac AJ; Letvin N; Hahn BH
    AIDS Res Hum Retroviruses; 2003 Sep; 19(9):817-23. PubMed ID: 14585212
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines.
    Ferrari G; Kostyu DD; Cox J; Dawson DV; Flores J; Weinhold KJ; Osmanov S
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1433-43. PubMed ID: 11018863
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice.
    Buffa V; Negri DRM; Leone P; Bona R; Borghi M; Bacigalupo I; Carlei D; Sgadari C; Ensoli B; Cara A
    J Gen Virol; 2006 Jun; 87(Pt 6):1625-1634. PubMed ID: 16690927
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenicity comparison between codon optimized HIV-1 CRF BC_07 gp140 and gp145 vaccines.
    Liu L; Wan Y; Xu J; Huang X; Wu L; Liu Y; Shao Y
    AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1396-404. PubMed ID: 18184083
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tat-neutralizing antibodies in vaccinated macaques.
    Tikhonov I; Ruckwardt TJ; Hatfield GS; Pauza CD
    J Virol; 2003 Mar; 77(5):3157-66. PubMed ID: 12584340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.